Physician
Emergency Medicine
Dr. Julio C. Medina Sr., MD
|
|
Give Review
Julio Medina is an expert in the field of Emergency Medicine. He over the years received 1 awards: "Whos Who in Medicine and Healthcare". Julio Medina is a published doctor. He has 28 publications published. The most current publication "Synthesis and SAR study of potent and selective PI3K inhibitors."
Publications
- Synthesis and SAR study of potent and selective PI3Kδ inhibitors.
- Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and...
- C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase Activators.
- Discovery of AM-7209, a Potent and Selective 4-Amidobenzoic Acid Inhibitor of the MDM2-p53 Interaction.
- Optimization beyond AMG 232: Discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein-protein interaction.
- Optimization of GPR40 Agonists for Type 2 Diabetes.
- Solving time-dependent CYP3A4 inhibition for a series of indole-phenylacetic acid dual antagonists of the PGD2 receptors CRTH2 and DP.
- Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4.
- Improving the Pharmacokinetics of GPR40/FFA1 Full Agonists.
- Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3.
- Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia.
- Novel Inhibitors of the MDM2-p53 Interaction Featuring Hydrogen Bond Acceptors as Carboxylic Acid Isosteres.
- Selective and Potent Morpholinone Inhibitors of the MDM2-p53 Protein-Protein Interaction.
- Discovery and optimization of 5-(2-((1-(phenylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)oxy)pyridin-4-yl)-1,2,4-oxadiazoles as novel gpr119 agonists.
- Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2-p53 Inhibitor in Clinical Development.
- Discovery and optimization of N-(3-(1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yloxy)phenyl)benzenesulfonamides as novel GPR119 agonists.
- Aminopyrazole-Phenylalanine Based GPR142 Agonists: Discovery of Tool Compound and in Vivo Efficacy Studies.
- Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles.
- Discovery and optimization of arylsulfonyl 3-(pyridin-2-yloxy)anilines as novel GPR119 agonists.
- Optimization of phenylacetic acid derivatives for CRTH2 and DP selective antagonism.
- Discovery of potent and specific CXCR3 antagonists.
- Optimization of triazoles as novel and potent nonphlorizin SGLT2 inhibitors.
- Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs.
- An inhibitory metabolite leads to dose- and time-dependent pharmacokinetics of (R)-N-{1-[3-(4-ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl}-N-py...
- CXCR3 antagonism impairs the development of donor-reactive, IFN-gamma-producing effectors and prolongs allograft survival.
- Gene expression analysis of host innate immune responses during Lethal H5N1 infection in ferrets.
- Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer.
Doctors Specialties
- Emergency Medicine
- Occupational Medicine
Accepted Insurances
Awards
- Whos Who in Medicine and Healthcare
Helpful Reviews
Similar Doctors
|
|
Dr. Jesus M. Marin, MD |
|
|
Dr. Dario L. Reyes Rivera, MD |
|
|
Dr. Roberto Velez Bermudez, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rene S. Lopez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alba N. Lopez, MD |
|
|
Dr. Angel A. Torres, MD |
|
|
Dr. Ramon Ochoa Salcedo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Raul Casas Lopez, MD |
|
|
Dr. Gardine M. Colon Guerra, MD |
|
|
Dr. Luis A. Sanchez Chevere, MD |